| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Across the last three months, Ligand Pharmaceuticals Incorporated's insiders have reduced their positions by a net 15,000 shares worth roughly $4.4M. In the past 30 days, 0 insiders bought and 1 sold.
On the other side, 1 insider reduced a position over the period.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 199.5K | $32.06M | - | |
| Other | 36.9K | $1.93M | -5,000 | |
| Dir | 33.6K | $8.54M | - | |
| CFO | 27.7K | $4.45M | - | |
| Dir | 3.8K | $1.13M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Oct 2, 2026 | Reardon Andrew | CLO &Secretary | Sale+OE | 5,000 | $304.07 | $1,520,345.87 | -13.6% | |
| Sep 3, 2026 | Reardon Andrew | CLO &Secretary | Sell | 5,000 | $286.09 | $1,430,434.39 | -12.0% | |
| Aug 3, 2026 | Reardon Andrew | CLO &Secretary | Sale+OE | 5,000 | $288.99 | $1,444,950.90 | -10.7% | |
| Jul 1, 2026 | Reardon Andrew | CLO &Secretary | Sale+OE | 5,000 | $313.28 | $1,566,376.99 | -10.7% | |
| Jun 16, 2026 | Sabba Stephen L | Director | Sale+OE | 2,145 | $254.00 | $544,830.00 | -6.0% | |
| Jun 1, 2026 | Reardon Andrew | CLO &Secretary | Sale+OE | 5,000 | $227.06 | $1,135,315.57 | -10.8% |